Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States
Autor: | Charmi Patel, Brahim Bookhart, Yen-Wen Chen, Christopher D Pericone, Bingcao Wu, Lawrence Blonde |
---|---|
Rok vydání: | 2020 |
Předmět: |
030213 general clinical medicine
medicine.medical_specialty endocrine system diseases Type 2 diabetes 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Glucosides Internal medicine medicine Empagliflozin Humans Hypoglycemic Agents Pharmacology (medical) Benzhydryl Compounds Canagliflozin Dapagliflozin Glycemic Glycated Hemoglobin Glycemic efficacy business.industry nutritional and metabolic diseases General Medicine medicine.disease United States Clinical trial Diabetes Mellitus Type 2 chemistry 030220 oncology & carcinogenesis Glycated hemoglobin business medicine.drug |
Zdroj: | Advances in Therapy. 38:594-606 |
ISSN: | 1865-8652 0741-238X |
Popis: | While several sodium glucose co-transporter 2 (SGLT2) inhibitors are approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM), there are no clinical trial data providing head-to-head comparisons of the efficacy and safety of these therapies. Real-world analyses can provide valuable evidence on the effectiveness of competing treatments. This study compared the real-world glycemic effectiveness of SGLT2 inhibitors in individuals with T2DM. Patients who initiated canagliflozin 300 mg versus empagliflozin 25 mg or dapagliflozin 10 mg were identified from the Optum® De-identified Clinformatics® Extended Data Mart–Date of Death database and propensity score matched. Achievement of HbA1c 9.0% (HEDIS poor control) after 6 months of treatment was calculated. Post-baseline HbA1c was similar in the canagliflozin and empagliflozin cohorts (7.65% versus 7.57%), as was percent of patients with HbA1c 9.0%. Post-baseline HbA1c was lower with canagliflozin versus dapagliflozin (7.58% versus 7.74%; P = 0.0247). The canagliflozin cohort was more likely to achieve HbA1c 9.0% was similar. In patients with T2DM, HbA1c outcomes were similar with canagliflozin and empagliflozin. Patients on canagliflozin versus dapagliflozin were more likely to have a lower HbA1c and reach HbA1c |
Databáze: | OpenAIRE |
Externí odkaz: |